https://www.selleckchem.com/pr....oducts/ngi-1ml414.ht
$400 per patient per month (PPPM), p 0.001). Of the total medical costs during the study period, the proportion of inpatients cost was 12.9 times higher than the outpatients cost ($1,730 and $134 PPPM, respectively). The median survival time was 3.53years from the first diagnosis of ATTR-CM, and the mean (SD) YPLL was 13.0 (7.7). Patients with ATTR-CM had short survival and high medical costs. To reduce the clinical and economic burdens, carefully examining manifestations of disease in patients can help with early diagnosis and